Altimmune (ALT) Stock Forecast & Price Target

Altimmune is a well-capitalized biopharmaceutical company with approximately $535 million in cash, cash equivalents, and short-term investments as of April 30, which is expected to fund operations through the PERFORMA 52-week readout in 2029. With the milestones achieved in the first quarter of 2021, including finalizing and submitting the protocol for PERFORMA and aligning with FDA and EMA feedback, Altimmune is now focused on executing its global pivotal Phase 3 trial for pemvidutide in MASH, with enrollment expected to begin in the second half of 2021. The company also has a diverse pipeline and multiple indications for pemvidutide, providing potential for further growth and value creation.

Altimmune is heavily reliant on the success of its candidate pemvidutide, which has a limited indication and unproven efficacy. With its sole focus on pemvidutide and a lack of diversification, the company faces significant risks and potential setbacks in its development and commercialization efforts. Additionally, ALT-801 is still in the early stages of development, with no current revenue and significant expenses, adding to the company's financial risk.